- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01087255
Caregivers and Electronic Medication Monitoring in Chronic Kidney Disease
Caregivers and Internet Based Monitoring to Improve Medication Use in HPHC Enrollees With Chronic Kidney Disease
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Adherence to medications is critical in managing chronic disease, yet it remains an issue across chronic conditions. Poor medication adherence leads to deteriorating health and subsequently to increased costs as a result of higher hospitalizations rates. Medication adherence in chronic kidney disease (CKD) is especially important because successful treatment can slow the progression to end-stage renal disease (ESRD), yet little research has focused on adherence in patients with early CKD. Numerous barriers to medication adherence exist, including the prescription of complex medication regimens, the often asymptomatic nature of early CKD, and the lack of social support for treatment adherence. While technology and support-based interventions show promise, there currently is no gold-standard approach to improving medication adherence. Thus, it is essential to pursue novel interventions that address barriers for patients with CKD to improve medication adherence and slow the progression to ESRD.
The long-range goal of this application is to improve medication adherence in chronic illness through the development of effective interventions that capitalize on patients' medication-taking context. The objective of this application, which is the next step to achieving that goal, is to pilot test the impact and acceptability of the MedMinder, a pillbox device that transmits medication-taking data via a secure internet-interface to patients, family members, and care managers, in a group of adult, Harvard Pilgrim Health Care (HPHC) members with CKD. To achieve this objective, in partnership with HPHC, we will recruit 120 members with diagnosed CKD stage III or IV to participate in a 6-month pre-post randomized-controlled trial. Participants will be randomized to either receive use of the MedMinder over a six-month period with access to telephone care management, or receive usual care of regular pillboxes with access to telephone care management.
Our primary aim is to test the feasibility and acceptability of the MedMinder intervention. The main components of the intervention include: (1) a plastic weekly pill box with programmable visual and auditory cues to prompt medication use, (2) generation of missed-dose alerts that can be sent via email, text message, or telephone to patients, family members, and HPHC care managers, (3) a secure internet site that permits customization of alerts and has graphical representations of medication use, and (4) aggregate adherence reports available to CKD care managers for patients who are participating in HPHC care management.
Our secondary aim is to assess the impact and acceptability of family and friend involvement in CKD member medication taking. We will document family and friend activities related to medication taking, the acceptability of family and friend involvement in member medication taking, and the impact such involvement has on medication use.
Findings of this proposed project would provide information on the feasibility of a technology-based adherence intervention, with medication-taking support, in patients with chronic disease. The results from this pilot will inform a future application for a more adequately powered study examining the intervention and measurement of structured support from others in medication taking.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Connie M Trinacty, PhD
- Phone Number: 617-509-9955
- Email: connie_trinacty@hphc.org
Study Contact Backup
- Name: Ashley J Beard, PhD
- Phone Number: 734-845-3813
- Email: ashlbear@med.umich.edu
Study Locations
-
-
Massachusetts
-
Wellesley, Massachusetts, United States, 02481
- Recruiting
- Harvard Pilgrim Health Care
-
Contact:
- Carla Rosenkras, RN, MPH
- Phone Number: 617-509-7565
- Email: carla_rosenkras@hphc.org
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- HPHC commercial- or Medicare-insured members with 2 or more distinct outpatient nephrology chronic kidney disease stage (CKD) III, IV, or V diagnoses in a 6-month period.
- 18 years old or older at the time they are identified as having CKD.
- An average of two prescription medications dispensed per month in the prior 6-months.
- Residence in MA, ME, or NH
- Residence in an area with MedMinder-participating cellular coverage (includes most major cellular carriers)
Exclusion Criteria:
- Dialysis or dialysis-related complication medical service claims in 6-month period preceding study entry.
- Atrius Health member
- Serious mental illness or cognitive dysfunction medical service claim in 6-month period preceding study entry
- Primary language other than English
- Unable to use a pillbox
- Have no eligible caregiver
Study Plan
How is the study designed?
Design Details
- Primary Purpose: SUPPORTIVE_CARE
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
NO_INTERVENTION: Usual Care
Usual care patients will have outpatient care and monitoring procedures, as determined by them and their health care providers.
|
|
EXPERIMENTAL: Electronic Pillbox Monitoring System
Usual care plus receive use of the wireless electronic pillbox and medication monitoring system
|
Daily exposure for six months
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
medication adherence
Time Frame: 6 months
|
We will calculate the proportion of days over a six month follow up period.
We will calculate quantity dispensed on all chronic prescriptions filled to measure the number of days a patient had chronic medications available during the study period ("days covered").
Patients who switch treatment from one medication to another within the same therapeutic category will count toward adherence.
Adherence is indicated by patients using >80% of prescribed doses.
|
6 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Connie M Trinacty, PhD, Harvard Medical School and Harvard Pilgrim Health Care Institute
- Study Director: Ashley J Beard, PhD, University of Michigan
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PF000123
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Kidney Disease
-
3-C Institute for Social DevelopmentUniversity of North Carolina, Chapel HillCompletedChronic Kidney Diseases | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage4 | Pediatric Kidney Disease | Chronic Kidney Disease stage3 | Chronic Kidney Disease Stage V | Chronic Kidney Disease, Stage IV (Severe) | Chronic Kidney Disease Stage 2 | Chronic Kidney Disease, Stage IUnited States
-
Universiti Putra MalaysiaRecruitingChronic Kidney Diseases | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage4 | Chronic Kidney Disease stage3 | Chronic Kidney Disease Requiring Chronic DialysisMalaysia
-
National Taiwan University HospitalCompletedChronic Kidney Disease stage4 | Chronic Kidney Disease stage3 | Chronic Kidney Disease Stage 2 | Chronic Kidney Disease Stage 1Taiwan
-
Centre Hospitalier le MansLe Mans UniversiteWithdrawnFatigue | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage3 | Chronic Kidney Failure | Chronic Kidney Disease, Stage 4 (Severe)
-
Centre Hospitalier le MansLe Mans UniversiteRecruitingFatigue | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage4 | Chronic Kidney Disease Stage 3BFrance
-
American Academy of Family PhysiciansUniversity of Colorado, Denver; National Institute of Diabetes and Digestive... and other collaboratorsCompletedChronic Kidney Disease | Chronic Renal Insufficiency | Chronic Kidney Insufficiency | Chronic Renal Diseases | Kidney Insufficiency, ChronicUnited States
-
Lund UniversityBaxter Healthcare Corporation; Universidad de CórdobaCompletedEnd Stage Kidney Disease | Chronic Kidney Disease Requiring Chronic DialysisArgentina
-
Centre Hospitalier Saint Joseph Saint Luc de LyonNot yet recruitingKidney Failure, Chronic | Diet Habit | Chronic Kidney Disease stage3 | Chronic Kidney Disease Stage 3B | Chronic Kidney Disease, Stage 3 (Moderate) | Chronic Kidney Disease Stage 3A (Disorder)France
-
A.C. AbrahamsCompletedEnd Stage Renal Disease | Chronic Kidney Disease | End Stage Kidney Disease | Chronic Kidney FailureNetherlands
-
Far Eastern Memorial HospitalActive, not recruitingMetabolic Syndrome | Chronic Disease | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease Stage 3 | Chronic Kidney Disease Stage 4 | Chronic Kidney Disease Stage 2 | Chronic Kidney Disease Stage 1Taiwan
Clinical Trials on Electronic Pillbox Monitoring System
-
Massachusetts General HospitalTerminated
-
McGill University Health Centre/Research Institute...National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedMedication Adherence | Kidney TransplantationCanada, United States
-
Columbia UniversityNational Heart, Lung, and Blood Institute (NHLBI)Completed
-
McGill University Health Centre/Research Institute...The Hospital for Sick Children; Children's Hospital of Philadelphia; Washington... and other collaboratorsCompletedMedication Adherence | Kidney TransplantationUnited States, Canada
-
University of WashingtonUnknownSerious Emotional Disturbance of YouthUnited States
-
Imperial College LondonAsthma UKCompletedAsthma in ChildrenUnited Kingdom
-
Rachel Vreeman, MD, MSBrown University; Moi UniversityCompletedTreatment Failure | Viral ResistanceKenya
-
Massachusetts General HospitalWithdrawnGastrointestinal Cancer
-
CAMC Health SystemWVCTSICompletedPeripheral Vascular Disease
-
Gaido HealthThe Guthrie ClinicUnknown